Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 2 Risk of early versus late relapse in molecular subtypes of breast cancer

From: Luminal-B breast cancer and novel therapeutic targets

  Early (<5 years) distant metastases (n= 831) Late (≥5 years) distant metastases (n= 652)
  HR 95% CI Pvalue HR 95% CI Pvalue
Age       
   (<50 years vs. ≥50 years) 0.77 (0.56, 1.06) NS 1.65 (0.97, 2.81) NS
Tumor size       
   (≤2 cm vs. >2 cm) 1.31 (0.91, 1.86) NS 1.18 (0.69, 2.01) NS
Histological grade       
   (2 vs. 1) 5.02 (1.80, 14.0) <0.01 0.92 (0.48, 1.76) NS
   (3 vs. 1) 7.22 (2.59, 20.2) <0.01 0.70 (0.31, 1.60) NS
Molecular subtype       
   Luminal-A 1 - - 1 - -
   Luminal-B 2.86 (1.70, 4.80) <0.01 0.65 (0.24, 1.72) NS
   HER2-positive 2.62 (1.50, 4.60) <0.01 1.41 (0.64, 3.12) NS
   Basal-like 2.83 (1.92, 4.82) <0.01 0.96 (0.54, 1.70) NS
  1. Data from five publicly available datasets from patients with node-negative tumors who did not receive adjuvant systemic therapy. Molecular subtype assignment according to the subtype clustering method [17]. CI, confidence interval; HR, hazard ratio; NS, nonsignificant.